{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:34:34Z","timestamp":1790696074412,"version":"4.1.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,24]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>IST leads to a response in nearly half, and to RBC transfusion independence in about a third, of selected lower-risk MDS patients. Hypocellularity of bone marrow and the use of horse ATG plus cyclosporine are associated with increased rates of transfusion independence.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018019414","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T15:55:16Z","timestamp":1532361316000},"page":"1765-1772","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":129,"title":["The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort"],"prefix":"10.1182","volume":"2","author":[{"given":"Maximilian","family":"Stahl","sequence":"first","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"DeVeaux","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yale School of Public Health, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"de Witte","sequence":"additional","affiliation":[{"name":"Department of Tumorimmunology, Radboudumc, Nijmegen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Neukirchen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[{"name":"Leukemia Program, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Brunner","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Steensma","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya R.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, NE;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum \u201cCarl Gustav Carus\u201d der Technischen Universit\u00e4t Dresden, Dresden, Germany;"},{"name":"German Cancer Consortium and National Center for Tumor Diseases Dresden, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cluzeau","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Nice, Nice, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro H.","family":"Prata","sequence":"additional","affiliation":[{"name":"Saint-Louis Hospital, University Paris 7, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Itzykson","sequence":"additional","affiliation":[{"name":"Saint-Louis Hospital, University Paris 7, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"Saint-Louis Hospital, University Paris 7, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Smith","sequence":"additional","affiliation":[{"name":"Epidemiology & Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen K.","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Verma","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, NE;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Nazha","sequence":"additional","affiliation":[{"name":"Leukemia Program, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Leukemia Program, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Prebet","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Florence, Azienda Ospedaliero Universitaria Carreggi, Florence, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Gore","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,7,23]]},"reference":[{"issue":"21","key":"2019111616535062900_B1","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/blood-2013-02-453068","article-title":"How we treat lower-risk myelodysplastic syndromes","volume":"121","author":"Fenaux","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2019111616535062900_B2","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1548::AID-CNCR16>3.0.CO;2-Y","article-title":"Immunosuppressive therapy for hypoplastic myelodysplastic syndrome","volume":"79","author":"Biesma","year":"1997","journal-title":"Cancer"},{"issue":"6","key":"2019111616535062900_B3","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/blood-2006-11-050526","article-title":"Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan","volume":"110","author":"Teramura","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2019111616535062900_B4","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00277-018-3302-0","article-title":"Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes","volume":"97","author":"Montoro","year":"2018","journal-title":"Ann Hematol"},{"issue":"3","key":"2019111616535062900_B5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.7326\/0003-4819-137-3-200208060-00007","article-title":"Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes","volume":"137","author":"Molldrem","year":"2002","journal-title":"Ann Intern Med"},{"issue":"7","key":"2019111616535062900_B6","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2012.083345","article-title":"A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction","volume":"99","author":"Komrokji","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"2019111616535062900_B7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2141.1997.4423249.x","article-title":"Antithymocyte globulin for patients with myelodysplastic syndrome","volume":"99","author":"Molldrem","year":"1997","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111616535062900_B8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1046\/j.1365-2141.2003.04136.x","article-title":"A pilot study of antithymocyte globulin (ATG) in the treatment of patients with \u2018low-risk\u2019 myelodysplasia","volume":"120","author":"Killick","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111616535062900_B9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1532\/IJH97.A10513","article-title":"Treatment of myelodysplastic syndrome with cyclosporin A","volume":"85","author":"Chen","year":"2007","journal-title":"Int J Hematol"},{"issue":"2","key":"2019111616535062900_B10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1532\/IJH97.07052","article-title":"A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response","volume":"86","author":"Ishikawa","year":"2007","journal-title":"Int J Hematol"},{"issue":"2","key":"2019111616535062900_B11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.leu.2401665","article-title":"Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele","volume":"14","author":"Okamoto","year":"2000","journal-title":"Leukemia"},{"issue":"35","key":"2019111616535062900_B12","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1200\/JCO.2010.29.7010","article-title":"Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions","volume":"28","author":"Sloand","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111616535062900_B13","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2007.11.9214","article-title":"Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy","volume":"26","author":"Sloand","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111616535062900_B14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","article-title":"Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33\/99","volume":"29","author":"Passweg","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111616535062900_B15","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/sj.leu.2403124","article-title":"Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes","volume":"17","author":"Yazji","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"2019111616535062900_B16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2141.1998.00551.x","article-title":"Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow","volume":"100","author":"Jon\u00e1sova","year":"1998","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111616535062900_B17","first-page":"322","article-title":"Autoimmune myelodysplasias","volume":"28","author":"Miescher","year":"1991","journal-title":"Semin Hematol"},{"issue":"5","key":"2019111616535062900_B18","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2141.2010.08145.x","article-title":"Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study","volume":"149","author":"Scott","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111616535062900_B19","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood-2002-09-2867","article-title":"Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome","volume":"101","author":"Steensma","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2019111616535062900_B20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2257.2002.00446.x","article-title":"Treatment of myelodysplasia with oral cyclosporin","volume":"24","author":"Atoyebi","year":"2002","journal-title":"Clin Lab Haematol"},{"issue":"5","key":"2019111616535062900_B21","first-page":"667","article-title":"Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes","volume":"91","author":"Broliden","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"2019111616535062900_B22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.seminhematol.2012.07.004","article-title":"Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab","volume":"49","author":"Parikh","year":"2012","journal-title":"Semin Hematol"},{"issue":"20","key":"2019111616535062900_B23","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019111616535062900_B24","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"12","key":"2019111616535062900_B25","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2019111616535062900_B26","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111616535062900_B27","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.leu.2405070","article-title":"A prognostic score for patients with lower risk myelodysplastic syndrome","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"2019111616535062900_B28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"2019111616535062900_B29","author":"R Development Core Team. R"},{"issue":"4","key":"2019111616535062900_B30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/17474086.2017.1297704","article-title":"Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends","volume":"10","author":"Stahl","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"2019111616535062900_B31","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1046\/j.1365-2141.1998.01085.x","article-title":"A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes","volume":"103","author":"Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes","year":"1998","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111616535062900_B32","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood.V95.4.1175.004k51_1175_1179","article-title":"Effect of recombinant human erythropoietin combined with granulocyte\/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome","volume":"95","author":"Thompson","year":"2000","journal-title":"Blood"},{"issue":"2","key":"2019111616535062900_B33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood-2003-07-2252","article-title":"Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial","volume":"104","author":"Casadevall","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2019111616535062900_B34","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","article-title":"Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)","volume":"114","author":"Greenberg","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2019111616535062900_B35","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/cncr.30585","article-title":"Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications","volume":"123","author":"Stahl","year":"2017","journal-title":"Cancer"},{"issue":"14","key":"2019111616535062900_B36","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111616535062900_B37","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111616535062900_B38","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"issue":"25","key":"2019111616535062900_B39","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","article-title":"Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents","volume":"34","author":"Santini","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111616535062900_B40","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"2019111616535062900_B41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood.V126.23.94.94","article-title":"Low-dose hypomethylating agents (HMAs) are effective in patients (Pts) with low- or intermediate-1-risk myelodysplastic syndrome (MDS): a report on behalf of the MDS clinical research consortium","volume":"126","author":"Short","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111616535062900_B42","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1038\/bcj.2014.8","article-title":"Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial","volume":"4","author":"Tobiasson","year":"2014","journal-title":"Blood Cancer J"},{"issue":"8","key":"2019111616535062900_B43","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3324\/haematol.2015.140988","article-title":"A randomized phase II trial of azacitidine +\/- epoetin-\u03b2 in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents","volume":"101","author":"Th\u00e9pot","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"2019111616535062900_B44","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2002-11-3325","article-title":"A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"issue":"Suppl","key":"2019111616535062900_B45","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.clml.2016.02.017","article-title":"Immunosuppressive therapy: exploring an underutilized treatment option for myelodysplastic syndrome","volume":"16","author":"Haider","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2019111616535062900_B46","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/sj.leu.2404747","article-title":"Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin","volume":"21","author":"Lim","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"2019111616535062900_B47","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.leu.2403239","article-title":"A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes","volume":"18","author":"Stadler","year":"2004","journal-title":"Leukemia"},{"issue":"5","key":"2019111616535062900_B48","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1056\/NEJMoa1103975","article-title":"Horse versus rabbit antithymocyte globulin in acquired aplastic anemia","volume":"365","author":"Scheinberg","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111616535062900_B49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000203403","article-title":"ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia--systematic review and meta-analysis","volume":"120","author":"Gafter-Gvili","year":"2008","journal-title":"Acta Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/14\/1765\/881160\/advances019414.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/14\/1765\/881160\/advances019414.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T21:54:09Z","timestamp":1573941249000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/14\/1765\/16249\/The-use-of-immunosuppressive-therapy-in-MDS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,23]]},"references-count":49,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,7,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018019414","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,23]]}}}